SCHEMBL1490575

SCHEMBL1490575

Cc1c(C)n2nnnc2c2nc(CCl)n(CCCCNC(=O)C(C)C)c12

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.35
KMT2A Q03164 2/20 0.33
MTNR1A P48039 2/20 0.33
MTNR1B P49286 2/20 0.33
MEN1 O00255 1/20 0.33
HTT P42858 1/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
GAA P10253 1/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
RECQL P46063 1/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490809 0.91
SCHEMBL1490240 0.85 HTR1A (0.41) BRD4KMT2AMEN1CYP2D6CYP2C9
SCHEMBL1490732 0.82 TLR7 (0.42)
SCHEMBL5027913 0.82 MEN1 (0.36) KMT2AMEN1HTTGAACYP2C19
SCHEMBL1490742 0.82 EPHX1 (0.41) BRD4
Hydrochloric Acid SCHEMBL1490638 0.79 TLR7 (0.34)
SCHEMBL1490694 0.73 HTR1A (0.37) BRD4KMT2AMEN1CYP2D6CYP2C9
SCHEMBL1490786 0.73 HTR1A (0.37) BRD4KMT2AMEN1CYP2D6CYP2C9
SCHEMBL5030364 0.72 MEN1 (0.30) KMT2AMEN1CYP2D6CYP2C9CYP2C19
SCHEMBL5030447 0.72 TLR7 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598192-B2 Hydroxylamine substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-12-03 US disclosed
US-7897767-B2 Oxime substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-20090105295-A1 HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-04-23 US disclosed
US-20090042925-A1 OXIME SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105295-A1 HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES IL2, IL4, IFNG BRD4 89/4885KMT2A 1555/4885MTNR1A 386/4885
US-20090042925-A1 OXIME SUBSTITUTED IMIDAZOQUINOLINES IFNG, IL2, IRF3 BRD4 335/4885KMT2A 1931/4885MTNR1A 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.